Trials / Terminated
TerminatedNCT00543712
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRO95780 | Intravenous repeating dose |
Timeline
- Start date
- 2007-05-31
- Primary completion
- 2008-05-05
- Completion
- 2008-05-05
- First posted
- 2007-10-15
- Last updated
- 2022-12-13
Locations
4 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT00543712. Inclusion in this directory is not an endorsement.